Following its recent reprioritization of clinical programs and corporate restructuring, Instil expects its cash runway to extend into 2025, excluding the potential financing or other monetization of its Tarzana manufacturing site. Instil intends to provide further updates on its pre-clinical pipeline in 2023, including the potential to nominate additional CoStAR candidates and novel TIL technologies for clinical development.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on TIL:
- Instil Bio Announces Resumption of Clinical Trial of CoStAR-TIL Candidate ITIL-306 in Lung, Ovarian, and Renal Cancer
- Instil Bio price target lowered to $5 from $14 at Baird
- Instil Bio discontinues ITIL-168 clinical programs
- Instil Bio prioritizes CoStAR-TIL program, reduces headcount by 60%
- Instil Bio treatment of stage IB2 to IV cervical cancer granted orphan status
